Description du projet
Personal Health Systems
In order to improve treatment of diabetes patients at home, the main goal of AP@Home is to build and evaluate an artificial pancreas (AP). The AP will allow automated glucose control: It monitors your blood glucose (sugar) levels and a software algorithm calculates how much insulin to deliver at any time via a built-in insulin infusion pump.
Normally, insulin is given either by injections or via continuous infusion pumps. However, blood glucose levels can be greatly affected by many factors such as diet, physical activity, illness and stress so that it is difficult for patients to judge how much insulin they need.
The automated artificial pancreas could not only improve the quality of life for people with insulin treated diabetes but also reduce the escalating healthcare cost burden.
In the first phase of the AP@home project, the currently available AP algorithms were tested with monitoring systems and insulin pumps already on the market, using a “two-port” approach that requires two skin punctures to attach the glucose monitor and the insulin pump. In this stage, the aim was to improve the accuracy of the glucose sensors and the safety and effectiveness of the algorithms that relate insulin delivery to blood glucose levels.
In parallel, innovative AP systems were developed that combine an insulin pump and a CGM system into a single device that uses only one access point through the skin. In the final year of the 4-year project, the performance of the newly created AP system, including remote monitoring facilities, will be compared with standard intensive insulin therapy in daily life in a multinational controlled trial.
The objective of AP@home is to build and evaluate an artificial pancreas (AP) with automated closed loop glycaemic control for insulin treated patients with diabetes. AP systems require algorithms using blood glucose levels obtained via glucose monitoring for controlling subcutaneous insulin administration. First, well established subcutaneous continuous glucose sensors and insulin pumps will be combined to improve and verify the functionality of enhanced closed-loop algorithms. We will advance algorithm quality, improve sensors by bringing their accuracy below the desired 5% error level and add a remote hypoglycaemia alarm. Second, in parallel, two AP systems will be developed by combining an insulin pump and a sensor into a single device, using only one access point through the skin ("single-port"). Thereby the need to puncture the skin twice, once for the glucose sensor and once for the insulin infusion, can be avoided ("two-port"). If proven successful in computer simulations we will evaluate the best selected single-port system under clinical conditions.Deliverables include: description of more precise glucose sensing methods; description of system integration of the two-port and both single-port AP systems; validation of prototypes in the clinic and at home. In a multinational controlled trial AP performance will be compared with standard intensive insulin therapy in daily life.Impact of the project includes strengthened competitiveness of European industry across a complete value chain involving large, mid-sized and small companies, enabling Europe to lead progress in AP systems. Also, the project will put European research and clinical organizations in leading positions with an increased number of high-skilled jobs in the medical device industry. Finally, diabetes care will be simplified, quality of life of patients with diabetes will be improved and diabetes related complications and health costs will diminish in the long run.
Champ scientifique
Appel à propositions
FP7-ICT-2009-4
Voir d’autres projets de cet appel
Régime de financement
CP - Collaborative project (generic)Coordinateur
41460 Neuss
Allemagne